Please login to the form below
Remdesivir
This page shows the latest Remdesivir news and features for those working in and with pharma, biotech and healthcare.
FDA approves COVID-19 treatment for those under the age of 12
The treatment – also known as remdesivir – is designed for patients who are older than 28 days, weighing at least 3kg and have either been hospitalised with COVID-19 or have the ... She added: “We need proven antiviral treatment options, like
Latest news
-
Gilead’s Veklury significant decreases risk of hospitalisation for COVID-19 patients
patients. The studies, conducted by Gilead Sciences, revealed considerable insights into the use of Veklury (remdesivir) for the treatment of both hospitalised and non-hospitalised patients with COVID-19.
-
Results from trial show Eli Lilly’s COVID-19 drug improves survival rates
The benefit of baricitinib proved to be consistent regardless of which other COVID-19 treatments the patients were also receiving, including tocilizumab, corticosteroids or remdesivir.
-
FDA restricts use of certain antibody treatments for COVID-19
The statement notes that while restrictions have been made on Regeneron and Lilly treatments at this time, there are still several therapy options, including Paxlovid, sotrovimab, Veklury (remdesivir) and molnupiravir, that
-
Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19
While we continue to advance remdesivir to benefit more patients in multiple settings, we are also advancing our investigational oral compounds. ... These are based on the same antiviral mechanism of action as remdesivir and a phase 1 trial for our oral
-
US regulators set to approve oral antiviral against COVID-19
Oral medications like molnupiravir and Paxlovid are significantly more convenient than the injectable COVID-19 treatments that are currently being used, including Gilead’s Veklury (remdesivir).
More from news
Approximately 12 fully matching, plus 42 partially matching documents found.
Latest Intelligence
-
The search for effective drug treatments for COVID-19
Trials) evaluating five-day and ten-day dosing durations of remdesivir in patients with severe disease. ... remdesivir”. Can you offer more details about the studies published in the aforementioned peer-reviewed journals?
-
Working together against COVID-19
Gilead shared some positive updates on social media about remdesivir but did not address all HCP concerns. ... Subsequently, Gilead dropped remdesivir’s orphan drug designation based on its potential as a coronavirus treatment.
-
COVID-19: the race to find a vaccine
A subsequent leak about the apparent failure of remdesivir in a Chinese trial then dampened expectations again. ... Yet, it is unlikely that any of the drugs will be a panacea, with Jefferies analysts saying remdesivir “might be modestly helpful”.
-
As COVID-19 takes over the world, biopharma fights back
An experimental antiviral: Gilead’s remdesivir. Gilead’s remdesivir, an experimental antiviral drug, is arguably the most-talked about potential treatment for COVID-19. ... Lane is currently overseeing ongoing studies at the US National Institutes of
More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Biogen and Happify Health team up to create digital platform for MS patients
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy
- Bristol Myers Squibb announces positive trial results for treatment of MS
- FDA grants Pfizer/BioNTech’s COVID-19 vaccine emergency use authorisation for infants
- Virtual MSL/Sales training programs and events
- 6 trends shaping the future of personalized medicine
- Omnichannel strategies to revolutionize the healthcare professional experience
- The digital-first launch: the key to connected stakeholder experiences?
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Bristol Myers Squibb announces positive trial results for treatment of MS
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Roche shares new positive Ocrevus data for MS patients
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s
- Phase 3 trial initiated to evaluate AZ's Saphnelo in lupus nephritis
- New virtual health and care report from WHO and Novartis calls for ‘critical action’
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Virtual MSL/Sales training programs and events
- Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
- Omnichannel strategies to revolutionize the healthcare professional experience
- Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
